| Original language | English (US) |
|---|---|
| Pages (from-to) | 1190-1192.e3 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 138 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 1 2016 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology, Vol. 138, No. 4, 01.10.2016, p. 1190-1192.e3.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Food-specific IgG4 is associated with eosinophilic esophagitis
AU - Wright, Benjamin L.
AU - Kulis, Mike
AU - Guo, Rishu
AU - Orgel, Kelly A.
AU - Wolf, W. Asher
AU - Burks, A. Wesley
AU - Vickery, Brian P.
AU - Dellon, Evan S.
N1 - Funding Information: This study was funded by the National Institutes of Health (grant nos. T32 AI007062 to B.L.W., K23 DK090073 to E.S.D., and T32 DK007634 to W.A.W.). This project was also supported in part by a Translational Team Science Award with funding provided by the UNC School of Medicine and the National Center for Advancing Translational Sciences, National Institutes of Health, through grant award number UL1TR001111. Funding Information: Disclosure of potential conflict of interest: B. L. Wright receives research support from the National Institutes of Health (NIH). M. Kulis and W. A. Wolf receive research support from the NIH. A. W. Burks receives research support from the NIH; serves on the board of the American Academy of Allergy, Asthma & Immunology, Food Allergy Research and Education (FARE), National Institutes of Health Allergy, Immunology, and Transplantation Research Committee, National Institutes of Health Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section, Stallergenes, and World Allergy Organization; serves as a consultant for ActoGeniX, Adept Field Solutions, Dow AgroSciences, ExploraMed Development, LLC, Genentech, GLG Research, Inc, Insys Therapeutics, Merck, Regeneron Pharmaceuticals, Inc, Sanofi-Aventis US Inv, SRA International, Valeant Pharmaceuticals North America, LLC, and Epiva Biosciences, Inc; provides testimony for Friday I Eldrege & Clark; receives royalties from the American Society for Microbiology; and has stock in Allertein and Mastcell Pharmaceuticals, Inc. B. P. Vickery receives research support from the NIH and has stock in Aimmune Therapeutics. E. S. Dellon receives research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the editor
PY - 2016/10/1
Y1 - 2016/10/1
UR - http://www.scopus.com/inward/record.url?scp=84964637891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964637891&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2016.02.024
DO - 10.1016/j.jaci.2016.02.024
M3 - Article
C2 - 27130859
AN - SCOPUS:84964637891
SN - 0091-6749
VL - 138
SP - 1190-1192.e3
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 4
ER -